Axsome Therapeutics and Shopify: Potential Growth Stocks to Watch for 2030
Axsome Therapeutics
Axsome Therapeutics has shown above-average returns fueled by clinical and regulatory advancements, including the launch of Auvelity for depression treatment in 2022.
Important treatments in the pipeline, such as AXS-12 for cataplexy, and Auvelity for Alzheimer's agitation show potential and innovation.
Axsome's revenue growth has been impressive despite remaining unprofitable, positioning it for significant growth by the end of the decade.
Shopify
Shopify excels in helping merchants develop online storefronts, offering various tools and integrations for business success.
An expected continuous growth of the e-commerce industry and high switching costs for merchants make Shopify a strong contender for long-term investment.
The conclusion highlights Axsome Therapeutics and Shopify as promising picks with potential standout growth by 2030.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.